SLC5A2 and myocardial infarction: SUCRA scores (dapagliflozin, 0.66; empagliflozin, 0.81; and placebo, 0.03) further support the potential benefits of both SGLT2 inhibitors in myocardial infarction risk reduction, with empagliflozin slightly edging out dapagliflozin in this ranking.